title: Anti-VEGF Therapy with Bevacizumab--limited cardiovascular toxicity.
abstract: OBJECTIVE
  This analysis was conducted to evaluate cardiovascular toxicity of commonly used anti-VEGF therapeutic agent, bevacizumab, in treating patients with cancer.
  
  
  METHODS
  Clinical studies evaluating the efficacy and safety of bevacizumab-based regimens on response and safety for patients with cancer were identified using a predefined search strategy, allowing cardiovascular toxicity and other side effects of treatment to be estimated.
  
  
  RESULTS
  In bevacizumab based regimens, 4 clinical studies including 282 patients with advanced cancer (including gliomas, cervical, breast and ovarian cancer) were considered eligible for inclusion. These bevacizumab-based regimens included docetaxel, irinitecan and carboplatin. Systematic analysis suggested that, of 282 patients treated by bevacizumab based regimens, hypertension and thrombo-embolism occurred in 2.5% (7/282), while only 3 patients reported cardiovascular events (1.1%). No treatment related death occurred in bevacizumab based treatment.
  
  
  CONCLUSIONS
  This systemic analysis suggests that bevacizumab based regimens are associated with reasonable and accepted cardiovascular toxicity when treating patients with gliomas, cervical, breast and ovarian cancer.
authors.affiliation: Department of Cardiology, Cangzhou Central Hospital of HeBei, CangZhou, China E-mail : kkllmyt918@163.com.
authors.forename: Jing
authors.initials: J
authors.lastname: Yu
authors.forename: Xu-Fen
authors.initials: XF
authors.lastname: Cao
authors.forename: Ye
authors.initials: Y
authors.lastname: Zheng
authors.forename: Rong-Cheng
authors.initials: RC
authors.lastname: Zhao
authors.forename: Li-Qiu
authors.initials: LQ
authors.lastname: Yan
authors.forename: Lei
authors.initials: L
authors.lastname: Zhao
authors.forename: Jia-Wang
authors.initials: JW
authors.lastname: Wang
mesh_terms: D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D000068258:Bevacizumab; D002318:Cardiovascular Diseases / Q000139:chemically induced*; D005500:Follow-Up Studies; D006801:Humans; D015201:Meta-Analysis as Topic; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000473:pathology; D009367:Neoplasm Staging; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology; D011379:Prognosis; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab